Pay in 4 interest-free payments of $6.43 Learn more
Ships within 48 hours · Estimated delivery Oct 14 - Oct 19
Reference: Cui C et al
We look forward to working with Ascendis to explore the potential of the TransCon technology platform to reduce the dosing frequency of GLP-1 receptor agonists and other treatments for cardiometabolic diseases. GLP-1 treatments are a class of diabetes and obesity medications that mimic a hormone that regulates blood sugar and suppresses appetite
Combining all three targets allows for synergistic metabolic benefits , while GLP-1 and GIP help buffer the blood sugarraising effect of glucagon [7]
Dietary supplementation is still important, however, particularly for gastrointestinal health, as the absorbed glutathione in food can directly help to detoxify the small intestine and improve overall nutrient absorption
The most frequently reported adverse effects include: Nausea and vomiting affecting 20-44% of patients (varies by product), particularly during dose escalation Diarrhoea experienced by approximately 18-30% of users depending on the specific medication Constipation occurring in around 19-24% of patients Abdominal pain or discomfort reported by 15-25% of individuals Reduced appetite whilst therapeutically desired, this can sometimes be excessive Dyspepsia and acid reflux affecting a smaller proportion of users These gastrointestinal effects typically emerge during the initial weeks of treatment or following dose increases
US$ 20.55
US$ 27.53
US$ 23.88
US$ 22.14
